Literature DB >> 8120410

Ras mutations in human melanoma: a marker of malignant progression.

N J Ball1, J J Yohn, J G Morelli, D A Norris, L E Golitz, J P Hoeffler.   

Abstract

In this study we address whether there is an association between ras mutations and disease progression in malignant melanoma. DNA was extracted from 100 paraffin-embedded melanomas and sequences around the 12th, 13th and 61st codons of N-, H-, and K-ras were amplified using the polymerase chain reaction and probed for single base pair mutations using synthetic oligonucleotide probes. Thirty-six melanomas contained mutations, which in 25 cases (69%) occurred at the 61st codon of N-ras. The results from dot blot hybridizations were confirmed by subcloning and sequencing the polymerase chain reaction products from two tumors. No ras mutations were found in Clark's level I melanomas, whereas 19% of level II and 45% of the more advanced primary tumors contained ras mutations (Chi squared test: p < 0.05). The median Breslow thickness of primary melanomas with ras mutations was 0.72 mm, significantly thicker than the 0.42 mm of melanomas without mutations (Mann-Whitney U test, p = 0.042). Ras mutations were found more frequently in primary tumors from continuously exposed skin (56%) than tumors from intermittently or non-sun exposed sites (21%). Fifty percent of locally recurrent and 47% of metastatic melanomas had ras mutations. We conclude that ras mutations occur in a subset of melanomas from sun-exposed skin as a feature of tumor progression.

Entities:  

Mesh:

Year:  1994        PMID: 8120410     DOI: 10.1111/1523-1747.ep12371783

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  51 in total

1.  Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells.

Authors:  M Kortylewski; P C Heinrich; M E Kauffmann; M Böhm; A MacKiewicz; I Behrmann
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

2.  Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.

Authors:  Yibing Ruan; Anna Kovalchuk; Aarthi Jayanthan; Xueqing Lun; Yoji Nagashima; Olga Kovalchuk; James R Wright; Alfredo Pinto; Adam Kirton; Ronald Anderson; Aru Narendran
Journal:  Neuro Oncol       Date:  2014-11-12       Impact factor: 12.300

3.  Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.

Authors:  Yafei Li; Zhifu Sun; Julie M Cunningham; Marie C Aubry; Jason A Wampfler; Gary A Croghan; Cassandra Johnson; Danli Wu; Jeremiah A Aakre; Julian Molina; Liewei Wang; V Shane Pankratz; Ping Yang
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

Review 4.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

Review 5.  Molecular targets in melanoma: time for 'ethnic personalization'.

Authors:  Shane Y Morita; Svetomir N Markovic
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

6.  Clinical correlates of NRAS and BRAF mutations in primary human melanoma.

Authors:  Julie A Ellerhorst; Victoria R Greene; Suhendan Ekmekcioglu; Carla L Warneke; Marcella M Johnson; Carolyn P Cooke; Li-E Wang; Victor G Prieto; Jeffrey E Gershenwald; Qingyi Wei; Elizabeth A Grimm
Journal:  Clin Cancer Res       Date:  2010-10-25       Impact factor: 12.531

7.  Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  S Martín-Algarra; M T Fernández-Figueras; J A López-Martín; A Santos-Briz; A Arance; M D Lozano; A Berrocal; J J Ríos-Martín; E Espinosa; J L Rodríguez-Peralto
Journal:  Clin Transl Oncol       Date:  2013-10-16       Impact factor: 3.405

8.  Novel targeted therapies for the treatment of metastatic melanoma.

Authors:  Ragini Kudchadkar
Journal:  Ochsner J       Date:  2010

9.  Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.

Authors:  Christian Posch; Homayoun Moslehi; Luzviminda Feeney; Gary A Green; Anoosheh Ebaee; Valentin Feichtenschlager; Kim Chong; Lily Peng; Michelle T Dimon; Thomas Phillips; Adil I Daud; Timothy H McCalmont; Philip E LeBoit; Susana Ortiz-Urda
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

Review 10.  The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease.

Authors:  Yue Zhao; Tian-Yu Wu; Meng-Fei Zhao; Chao-Jun Li
Journal:  J Biol Chem       Date:  2020-03-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.